Pirarubicin-Based versus Doxorubicin-Based Osteosarcoma Chemotherapy-Reference-Cited by-同舟云学术

Pirarubicin-Based versus Doxorubicin-Based Osteosarcoma Chemotherapy

Published:2002-06 Issue:6 Volume:36 Page:996-999
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Shinozaki Tetsuya¹,Watanabe Hideomi²,Yanagawa Takashi³,Shirakura Kenji⁴,Takagishi Kenji⁵

Affiliation:

1. Tetsuya Shinozaki MD DMSc, Assistant Professor, Department of Orthopedic Surgery, Faculty of Medicine, Gunma University, Gunma, Japan

2. Hideomi Watanabe MD DMSc, Assistant Professor, Department of Orthopedic Surgery, Faculty of Medicine, Gunma University

3. Takashi Yanagawa MD, Postgraduate Student, Department of Orthopedic Surgery, Faculty of Medicine, Gunma University

4. Kenji Shirakura MD DMSc, Associate Professor, Department of Orthopedic Surgery, Faculty of Medicine, Gunma University

5. Kenji Takagishi MD DMSc, Professor, Department of Orthopedic Surgery, Faculty of Medicine, Gunma University

Abstract

OBJECTIVE: To conduct a retrospective evaluation of tetrahydropyranyladriamycin (PIR)-based combination chemotherapy for osteosarcomas in comparison with doxorubicin (DOX)-based regimens to determine differences in response and toxicities between DOX- and PIR-containing regimens. METHODS: Toxicities and response rates of the 2 anthracyclines given as combination chemotherapy were assessed in patients with osteosarcoma, with 19 patients receiving PIR-based and 11 receiving DOX-based regimens. RESULTS: The survival of osteosarcoma patients treated with PIR was significantly better than that with DOX (p = 0.023) based on 2-year follow-up. Adverse effects such as mucositis and diarrhea were also less pronounced in the PIR cohort. CONCLUSIONS: PIR-based combination chemotherapy might be a useful and safe chemotherapeutic strategy for osteosarcomas compared with DOX regimens. Further assessment is necessary to confirm the safety and efficacy of this treatment.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1345/aph.1A187

Reference23 articles.

1. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

2. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation

3. Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

4. Phase II evaluation of adriamycin in human neoplasia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirarubicin reduces USP22 expression by inhibiting CREB‑1 phosphorylation in HeLa cells;Experimental and Therapeutic Medicine;2019-03-27

2. Intracellular Fate of Polymer Therapeutics Investigated by Fluorescence Lifetime Imaging and Fluorescence Pattern Analysis;Physiological Research;2016-09-17

3. Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin;Autophagy;2016-05-10

4. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?;Medical Oncology;2014-11-29

5. LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy;Molecular Medicine Reports;2014-10-09